Organigram Confident No Risk to TSXV Listing
19 10월 2017 - 3:58AM
Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the
“Company” or “Organigram”), a leading licensed producer of medical
marijuana based in Moncton, New Brunswick, is providing
clarification to the Company’s stakeholders in response to the
recent notices issued by the TSX Venture Exchange (“TSXV”) and the
Canadian Securities Administrators.
Organigram is confident that the TSXV
announcement will have no impact on our business or ongoing listing
with the TSXV. Organigram has no investment or ownership in
any US entity nor does it provide any products or services to US
entities.
To confirm, the Company’s arrangement with TGS
International LLC (“TGS”) -as initially disclosed September 1,
2016- does not involve the provision of products or services to TGS
nor does Organigram possess any ownership interest in TGS.
TGS is a vertically integrated seed-to-sale conglomerate generally
regarded as having the best-in-class technological expertise in
extract technology. Organigram’s exclusive arrangement with
TGS focuses on leveraging TGS’s product development knowledge and
provides exclusive Canadian access to industry-leading intellectual
property, technology, engineering, product formulations and
packaging ensuring that Organigram is well positioned for the
anticipated rapid development of the edibles market in Canada.
For more information about Organigram,
visit: www.organigram.ca
About Organigram Holdings
Inc.
Organigram Holdings Inc. is a TSX Venture
Exchange listed company whose wholly owned subsidiary, Organigram
Inc., is a licensed producer of medical marijuana in Canada.
Organigram is focused on producing the highest quality,
condition-specific medical marijuana for patients in Canada.
Organigram's facility is located in Moncton, New Brunswick and the
Company is regulated by the Access to Cannabis for Medical Purposes
Regulations (“ACMPR”).
Organigram has been ranked in the top 10 Clean
Technology & Life Sciences Sector on the TSX Venture Exchange
50.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking
information which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors - including the
availability of funds, the results of financing efforts, crop
yields - that could cause actual results to differ materially from
the Company's expectations are disclosed in the Company's documents
filed from time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The Company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward looking
statements, whether as a result of new information, future events
or otherwise.
For more information, visit www.Organigram.ca
For further information, please contact:
Giselle Doiron Director
of Investor and Media Relations (506) 801-8986 |
|
Greg Engel Chief
Executive Officer gengel@organigram.ca |
OrganiGram (TSX:OGI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
OrganiGram (TSX:OGI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024